Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19475281 | 0.88 | MOK (0.68) | MOKCYP2A13 | |
| SCHEMBL31590624 | 0.88 | MOK (0.68) | MOKCYP2A13 | |
| SCHEMBL31590498 | 0.84 | MOK (0.68) | MOKCYP2A13 | |
| SCHEMBL30834315 | 0.83 | MOK (0.67) | MOKCYP2A13 | |
| SCHEMBL30834313 | 0.83 | MOK (0.67) | MOKCYP2A13 | |
| SCHEMBL30834328 | 0.82 | MOK (0.64) | MOKCYP2A13 | |
| SCHEMBL31590313 | 0.82 | MOK (0.69) | MOKCYP2A13 | |
| SCHEMBL31590890 | 0.81 | MOK (0.66) | MOKCYP2A13 | |
| SCHEMBL31590934 | 0.81 | MOK (0.65) | MOKCYP2A13 | |
| SCHEMBL31590345 | 0.81 | MOK (0.68) | MOKCYP2A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192859-B2 | Quinoline compounds as modulators of RAGE activity and uses thereof | UNIV NEW YORK (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192859-B2 | Quinoline compounds as modulators of RAGE activity and uses thereof | UNIV NEW YORK (US) | 2021-12-07 | — | — | US | disclosed |
| US-20190194136-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | UNIV NEW YORK (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194136-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | UNIV NEW YORK (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017184547-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184547-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194136-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | AGER, HMGB1, GPR119 | MOK 4420/4885CYP2A13 3904/4885 |
| US-11192859-B2 | Quinoline compounds as modulators of RAGE activity and uses thereof | AGER, HMGB1, GPR119 | MOK 4420/4885CYP2A13 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.